Idorsia Ltd (SIX: IDIA) today announced positive top-line results of PRECISION, the Phase 3 study investigating aprocitentan, Idorsia’s dual endothelin receptor antagonist, for the treatment of patients whose blood pressure is not adequately controlled despite receiving at least triple antihypertensive therapy – known as resistant hypertension. Aprocitentan significantly reduced blood pressure when added to standardized combination background antihypertensive therapy in patients with resistant hypertension over 48 weeks of treatment. Hypertension is one of the most common cardiovascular risk factors,...